<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "https://jats.nlm.nih.gov/publishing/1.3/JATS-journalpublishing1-3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" dtd-version="1.3" xml:lang="en">
<front>
<journal-meta>
  <journal-id journal-id-type="publisher-id">58</journal-id>
  <journal-id journal-id-type="short-title">gdddr</journal-id>
  <journal-id journal-id-type="doi">10.31703/gdddr</journal-id>
  <journal-title-group>
    <journal-title>Global Drug Design &amp; Development Review</journal-title>
    <abbrev-journal-title abbrev-type="publisher">gdddr</abbrev-journal-title>
  </journal-title-group>
  <issn publication-format="print">2788-497X</issn>
  <issn publication-format="electronic">2788-4120</issn>
  <self-uri xlink:href="https://gdddrjournal.com"/>
  <publisher>
    <publisher-name>Humanity Publications</publisher-name>
    <publisher-loc>Pakistan</publisher-loc>
  </publisher>
</journal-meta>
<article-meta>
  <article-id pub-id-type="publisher-id">394818</article-id>
  <article-id pub-id-type="doi">10.31703/gdddr.2023(VIII-II).12</article-id>
  <article-id pub-id-type="other" specific-use="submission-id">5285</article-id>
  <article-version article-version-type="publisher">1.0</article-version>
  <article-categories>
    <subj-group subj-group-type="heading">
      <subject>article</subject>
    </subj-group>
  </article-categories>
  <title-group>
    <article-title xml:lang="en">Albumin Overview and Its Purification Method</article-title>
  </title-group>
<contrib-group>
  <contrib contrib-type="author" seq="1" corresp="yes">
    <name>
      <surname>Rehman</surname>
      <given-names>Bushra</given-names>
    </name>
    <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
    <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
    <xref ref-type="aff" rid="aff1"/>
    <xref ref-type="corresp" rid="cor1"/>
  </contrib>
  <contrib contrib-type="author" seq="2">
    <name>
      <surname>Ikram</surname>
      <given-names>Hira</given-names>
    </name>
    <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
    <xref ref-type="aff" rid="aff2"/>
  </contrib>
  <contrib contrib-type="author" seq="3">
    <name>
      <surname>Nasir</surname>
      <given-names>Rabia</given-names>
    </name>
    <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
    <xref ref-type="aff" rid="aff3"/>
  </contrib>
  <contrib contrib-type="author" seq="4">
    <name>
      <surname>Umar</surname>
      <given-names>Aiman</given-names>
    </name>
    <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
    <xref ref-type="aff" rid="aff4"/>
  </contrib>
  <aff id="aff1">
    <label>1</label>
    <institution-wrap>
      <institution>Rahman Medical Institute, Peshawar</institution>
    </institution-wrap>
    <named-content content-type="author-role">Assistant Professor</named-content>
    <addr-line>KP</addr-line>
    <country>Pakistan</country>
  </aff>
  <aff id="aff2">
    <label>2</label>
    <institution-wrap>
      <institution>Institute Biotechnology and Microbiology, Bacha Khan University, Charsadda</institution>
    </institution-wrap>
    <named-content content-type="author-role">Lecturer</named-content>
    <addr-line>KP</addr-line>
    <country>Pakistan</country>
  </aff>
  <aff id="aff3">
    <label>3</label>
    <institution-wrap>
      <institution>Center of Excellence in Marine Biology, Karachi</institution>
    </institution-wrap>
    <named-content content-type="author-role">Assistant Professor</named-content>
    <addr-line>Sindh</addr-line>
    <country>Pakistan</country>
  </aff>
  <aff id="aff4">
    <label>4</label>
    <institution-wrap>
      <institution>Department of Microbiology, Quaid I Azam University</institution>
    </institution-wrap>
    <named-content content-type="author-role">Assistant Professor</named-content>
    <addr-line>Islamabad</addr-line>
    <country>Pakistan</country>
  </aff>
</contrib-group>
<author-notes>
  <corresp id="cor1">Corresponding Author: Bushra Rehman, Assistant Professor, Rahman Medical Institute, Peshawar, KP, Pakistan.</corresp>
<fn fn-type="COI-statement" id="fn-coi">
  <p>The authors declare that they have no conflicts of interest.</p>
</fn>
<fn fn-type="ethics-statement" id="fn-ethics">
  <p>This study did not require formal ethics approval.</p>
</fn>
<fn fn-type="data-availability-statement" id="fn-data">
  <p>Data sharing is not applicable to this article.</p>
</fn>
</author-notes>
<pub-date pub-type="epub" date-type="pub" publication-format="electronic">
  <day>30</day>
  <month>06</month>
  <year>2023</year>
</pub-date>
<pub-date pub-type="collection">
  <month>06</month>
  <year>2023</year>
</pub-date>
<pub-date date-type="pub" publication-format="print">
  <day>22</day>
  <month>05</month>
  <year>2023</year>
</pub-date>
  <volume>8</volume>
  <issue>2</issue>
  <season>Spring</season>
  <fpage>89</fpage>
  <lpage>96</lpage>
  <history>
    <date date-type="accepted">
      <day>22</day>
      <month>05</month>
      <year>2023</year>
    </date>
  </history>
<funding-group>
  <funding-statement>
<p>The authors received no specific funding for this work.</p>
  </funding-statement>
</funding-group>
<permissions>
  <copyright-year>2023</copyright-year>
  <copyright-holder>Humanity Publications</copyright-holder>
  <license license-type="open-access" xml:lang="en" xlink:href="https://creativecommons.org/licenses/by/4.0/">
    <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License.</license-p>
  </license>
</permissions>
<self-uri content-type="text/html" xlink:href="https://gdddrjournal.com/article/albumin-overview-and-its-purification-method"/>
<self-uri content-type="pdf" xlink:href="https://gdddrjournal.com/pdf/gdddr/vwxOcbOfUw.pdf"/>
<supplementary-material id="suppl-pdf" content-type="pdf" xlink:href="https://gdddrjournal.com/pdf/gdddr/vwxOcbOfUw.pdf">
  <label>PDF</label>
  <caption>
    <title>Full Text PDF</title>
  </caption>
</supplementary-material>
  <abstract>
    <p>Drug researchers are currently studying the use of nanoparticles in drug delivery in great detail. In general, a medication&apos;s pharmacokinetic and tissue appropriation profiles can be changed, intracellular infiltration and appropriation can be improved, and a drug&apos;s absorption can be improved by dispersing the drug via the epithelium. The ability of nanoparticulate frameworks to tolerate physiological pressure—that is, their increased organic stability and oral conveyance plausibility—is one of their key advantages. As such, they offer a more appealing drug delivery solution than liposomes.</p>
  </abstract>
<kwd-group kwd-group-type="author-keywords">
  <kwd>Nanoparticles</kwd>
  <kwd>Pharmacokinetic</kwd>
  <kwd>Intracellular Infiltration</kwd>
  <kwd>Liposomes</kwd>
</kwd-group>
  <custom-meta-group>
    <custom-meta><meta-name>views</meta-name><meta-value>423</meta-value></custom-meta>
    <custom-meta><meta-name>downloads</meta-name><meta-value>0</meta-value></custom-meta>
    <custom-meta><meta-name>html-views</meta-name><meta-value>0</meta-value></custom-meta>
    <custom-meta><meta-name>google-scholar-citations</meta-name><meta-value>0</meta-value></custom-meta>
    <custom-meta><meta-name>crossref-citations</meta-name><meta-value>0</meta-value></custom-meta>
  </custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec-1">
  <title>Introduction</title>
<p>Furthermore, managing the surface characteristics, organisation, and milieu can result in the best possible pharmaceutical delivery example and its bio dispersion (Suri et al, 2007; Roco, 2003; Torchilin, 2008). Moreover, one notable benefit of nanoparticulate frameworks is their resistance to physiological pressure; however, they also show enhanced organic stability and oral delivery plausibility, which makes them a more appealing drug delivery option than liposomes (Sahoo &amp; Labhasetwar, 2008; Couvreur &amp; Vauthier, 2006; Kumar, 2000).</p><p>Numerous nano-sized transporters, including polymeric nanoparticles, strong lipid nanoparticles, ceramic nanoparticles, attractive nanoparticles, polymericmicelles, polymer-drug forms, nanotubes, nanowires, nanocages, and dendrimers, are being developed for a range of drug delivery applications (Sahoo et al., 2007). Polymeric nanoparticles can be synthesised using synthetic polymers (Fattal et al., 1998; Breunig et al., 2008), polysaccharides (Liu et al., 2008; Fernandez-Urrusuno et al., 1999), or proteins (Farrugia &amp; Groves, 1999).</p><p>Nanoparticles produced from naturally hydrophilic polymers have been shown to have enhanced drug loading capacity, biocompatibility, and perhaps reduced opsonization by the reticuloendothelial system (RES) through an aqueous steric barrier (Liu et al., 2008). Protein-based systems have been researched for the delivery of bioactives, nutrition, and medication. Casein, albumin, whey protein, and collagen are a few examples of these systems. Probiotic species and peptides; Kuijpers et al., 2000; Elzoghby et al., 2011). Proteins are a great source of raw materials. Materials, as they provide the benefits of synthetic polymers with absorbability and low degrading toxicity (Vandelli et al, 2001: Sahin et al, 2002) end goods.</p><p>Protein-based nanoparticles are particularly noteworthy among the various colloidal drug carrier systems that are presently being developed because of their benefits, which include enhanced stability during storage and in vivo. They are non-toxic and non-antigenic, and they are simpler to create than other drug delivery techniques (Langer et al., 2003; Rubino et al., 1993; Kommareddy &amp; Amiji, 2005; Azarmi et al., 2006). It has been demonstrated that albumin is a desirable macromolecular carrier that is non-toxic, biodegradable, immunogenic-negative, readily purified, and soluble in water. Due to these characteristics, it&apos;s a fantastic choice for injectable nanoparticle synthesis (Kratz et al., 1993; Rahimnejad et al., 2006).</p><p>The most prevalent protein in plasma, albumin is most recognised for its ability to bind to other proteins and for controlling lipid metabolism and vascular oncotic strain. To bind and transport several metabolites (Fasano et al, 2005; Quinlan et al, 2005). A plasma-derived product called therapeutic human serum albumin (HSA) is used to treat hypovolaemic shock, burn therapy, hypoproteinemia, and a number of other illnesses (Tullis, 1997; Tullis, 1977). Apart from its widely recognised characteristics, HSA has been demonstrated to elevate glutathione levels in peripheral blood cells (Cantin et al., 2000), a tripeptide essential for regular operation.immunological reactions in cells, lymphocytes, and humour (Droge et al., 1994). Conversely, HSA directly affects the management of Thus far, no on the other hand, HSA directly impacts the administration of It seems that this abundant plasma protein is not interfering with the actions of immune cells, since no immunological processes have been found to date. Furthermore, therapeutic preparations of HSA are commonly used as a negative control protein in research labs examining the immunomodulatory effects of therapeutic proteins like IVIg (Stohl &amp; Elliot, 1996; Modiano et al, 1997; Crow et al, 2001; Grandmont et al, 2003; Tha-In et al, 2007; Ephrem et al, 2008)</p><p>Bovine serum albumin, human serum albumin, and ovalbumin are the three kinds of albumin. Among these is ovaalbumin, a monomeric phosphoglycoprotein. A lot of people eat it (Elsadek &amp; Kratz, 2012). This multifunctional protein is composed of 385 protein units or amino acids. Its molecular structure includes four free sulfydryl groups and a disulfide link. The equivalent values for its molecular weight and isoelectric point are 4.8 Da and 47,000 Da, respectively (Oakenfull et al, 1997). Ovalbumin is used as a drug delivery technique, particularly in controlled drug delivery, because of its numerous desirable properties, including low cost, ease of availability, capacity to form gel networks, emulsion stabilisation, and pH- and temperature-sensitivity. Due to its affordability, medicinal value, natural abundance, and ease. Its mass is 69,323 Da and its density is 4.7 in water (at molecular weight and isoelectric point, 25OC) (Oakenfull et al, 1997). Instead of using bovine serum albumin, a human serum albumin replacement was utilised to prevent any potential in vivo immunologic reaction. Blood albumin is utilised. It is the most plentiful. A hydrophilic plasma protein with an extended half-life It has a half-life of 19 days and a molecular weight of 66,500 Da. According to Hirose et al. (2010), it contains 35 cysteinyl moieties, 17 disulfide bridges, and a sulfhydryl group.</p><p>A plasma protein with numerous uses is albumin. This protein is the main modulator of plasma oncotic pressure. Apart from that, there have been some oncotic changes. Pressure may be the source of the activation of HSA synthesis. Its tertiary structure allows it to bind to a wide range of compounds. These molecules include gases, metabolites, and foreign compounds such as medications. The sole mechanism for loaded HSA endocytosis that is thought to occur is receptor-mediated endocytosis; no evidence of an HSA receptor has been found. Additionally, it functions as a chaperone molecule, helping to fold proteins and avoiding the formation of new ones in disease-related aggregated proteins (Kragh-Hansen, 2013; Elzoghby et al, 2012; Sleep, 2015). The plasma that makes up the HSA is exposed to many types of oxidative stressors. The anti-oxidant function of this protein is well recognised; it aids in maintaining a fluid balance between compartments and restoring COP (Liumbruno et al, 2009). Treatment for hypoalbuminemia entails injecting 5 per cent, 20 per cent, or 25 per cent albumins that have been sterilised against viral infections for 10 to 11 hours at 60 to 0.5°C. The deactivation procedure. This sterilisation process is anticipated to produce denatured HSA (Kragh-Hansen et al., 2006; Dugaiczyk et al., 1982; Gerety &amp; Aronson, 1982; Fanali et al., 2007). Treatment for hypoalbuminemia entails injecting 5 per cent, 20 per cent, or 25 per cent albumins that have been sterilised against viral infections for 10 to 11 hours at 60 to 0.5°C. The deactivation procedure. This sterilisation process is anticipated to produce denatured HSA (Kragh-Hansen et al., 2006; Dugaiczyk et al., 1982; Gerety &amp; Aronson, 1982; Fanali et al., 2007). Clinical indications for albumin 4-5% solution include acute liver failure, cardiac bypass, and emergency therapy of hypovolemic shock. Fluids high in protein are confined (Tulisllis, 1977; Clowes et al, 1966). Many applications of albumin exist in the relevant field of research, such as supplementing cells, stabilising proteins, and cryopreservation. In a unique HSA application, peptides, a drug nanocarrier, and an oxygen transporter are combined ((Chen et al, 2013; Raoufinia et al, 2016; He et al, 2011).</p><p><break/></p><p>Albumin Market</p><p>The albumin market is expected to increase at a compound yearly growth rate of 9.6% from its 2016 worth of $5,381 million to $10,305 million by 2023. The most concentrated protein in blood plasma is called albumin. It performs several tasks, including maintaining oncotic strain and facilitating the passage of hormones and fatty acids. It is used to replace lost fluid and assist in restoring blood volume in the treatment of wounds, burns, operations, infections, and liver problems. It increases the stability of medications by reducing oxidation, aggregation, and surface absorption. Serum albumin comes in a variety of forms that are commonly used in medical settings.</p><p>Human serum albumin is made from human plasma, while bovine serum albumin is made from cow plasma. Conversely, recombinant albumin is produced in yeast and bacterial strains via recombinant techniques. The global albumin market is divided into three segments: commodity, application, and region. Recombinant albumin, bovine serum albumin, and human serum albumin are the three types of albumin that are available. Due to the product&apos;s large production, the human serum albumin category held the largest market share in 2016. This is expected to be the continuing pattern throughout the remainder of the projection. However, the recombinant albumin component is predicted to increase at a noteworthy CAGR of 11.4 per cent throughout the course of the projected period.</p><p>The market is divided into four regions: North America, Europe, Asia-Pacific, and The Caribbean and Latin America. North America and Europe had the largest market shares in 2016. In contrast, Asia-Pacific is anticipated to lead the market over the projection period because of its sizable patient base, growing disposable income, and improved awareness of albumin products. (Srivastava &amp; Jaiswal, 2018)</p>
</sec>
<sec id="sec-2">
  <title>Albumin Purification</title>
<p>Precipitation Using Ammonium Sulfate Salt</p><p>3 ml of produced serum was precipitated drop by drop into 3 ml of saturated ammonium sulphate on a magnetic stirrer. The mixture was then incubated at 4°C for a whole night. The pellet was soaked in water before cleaning. Five times saturated ammonium sulphate. For a full day at 4°C, the precipitate was dialyzed against Tris phosphate buffer (pH: 8.2) and PBS (pH: 7.2). The anti-HSA IgG was subsequently purified using ion exchange chromatography (Raoufinia et al, 2016).</p><p><break/></p><p>Albumin Purification using GFC</p><p>For condensation fractions up to fifty per cent, Amicon was utilised. The pH of the solution was adjusted to 5/2 by adding 1 M NaOH. The mixture was allowed to settle at 55°C for three hours before being cooled to 4°C overnight. also centrifuged for 20 minutes at 5000 xg. The albumin-containing solution&apos;s pH was raised to 6 using 1 M NaOH. The solution was put into a Sepharose G-100 gel filtration column (Raoufinia et al, 2018).</p><p><break/></p><p>Electrophoresis Analysis</p><p>The purity of various chromatographic fractions was evaluated in less restrictive conditions using cellulose acetate membrane electrophoresis (CAME) and sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). A 70 x 130 mm cellulose acetate membrane that was ready for CAME was used as the cathode area for the samples. For the electrophoresis, a continuous current of 0.7 mA/cm of membrane barbital buffer (pH 8.6, 0.05 mol/L sodium barbital) was employed for 20 minutes. On a 12 per cent gel, SDS-PAGE was performed at a steady voltage. Coomassie blue staining allowed for the visibility of the protein bands (Raoufinia et al., 2016).</p><p><break/></p><p>Affinity Chromatography</p><p>Liquid chromatography known as affinity chromatography uses affinity ligands, which are biological agents, as the stationary phase in the column. This strategy aims to purify analytics selectively and investigate biological interactions between molecules (Hag et al., 2012; Abdolalizadeh et al., 2013; Abdolalizadeh et al., 2012). Affinity chromatography was first developed for purification in 1968 (Cuatrecasas et al., 1968).</p><p><break/></p><p>Ion Exchange Chromatography</p><p>With its origins in the 1940s Nobel Prize-winning work of Moore and Stein (Moore et al., 1956), who separated amino acids on derivatized beads of polystyrene cross-linked with divinylbenzene, ion exchange is the most well-known and traditional method of protein chromatography. (Kovacs &amp; Guttman, 2013; Vasileva et al, 1981; Abdolalizadeh et al, 2008; Maleki and al, 2013) IEC frequently processes albumin and other proteins.</p><p>The anion exchange approach is the one that is used the most frequently among them (Vasiliva et al., 1981).</p><p>The procedure consists of three steps. Pre-treatment, polishing, and filtration are typical IEC processes. Most individuals are aware of the shortcomings of conventional chromatography methods, which include extended processing times, restricted flow rates, and other issues.</p><p>Improved adsorbers served as the foundation for the development of a revolutionary ion exchange membrane chromatography (IEM) technique that addressed these problems (Frerick et al., 2006). Simulation tests were carried out to compare the IEM with the IEC (Frerick et al., 2008).</p><p><break/></p><p>Chromatography Evaluation using SDS-PAGE Analysi</p><p>The purity of the fractions from the IEC was assessed by affinity chromatography under reducing conditions using the traditional Laemmeli technique in conjunction with SDS-PAGE. The separating gel had 12% polyacrylamide concentration, while the stacking gel had 4%. The electrophoresis procedure was carried out using the mini-PROTEAN electrophoresis apparatus, which is produced in the United States by Bio-Rad Laboratories. The protein bands were identified using CBB R-250 (Raoufinia et al., 2016).</p>
</sec>
<sec id="sec-3">
  <title>Heat Shock Method</title>
<p>The heat shock purification method can be used to purify albumin since it is more stable under temperature changes than other plasma proteins. Because of this, the albumin protein is resistant to heat up to 60 degrees Celsius, which may render a potential infection inactive (Raoufinia et al., 2016). Serum albumin was stabilised at 60 °C in pH 5 using 0.04 caprylic acid. In this state, additional serum proteins get denatured and precipitate as a liquid. After that, precipitation and ultrafiltration are used to concentrate albumin until a purity of roughly 98% is reached (Denizli, 2011).</p><p><break/></p><p>Critical Analysis</p><p>Albumin is an abundant protein in the body. Albumin has a major function in Nutrition, balancing osmotic pressure; maintaining iron deficiency and transport of body fluids. Albumin has a very important role in the research and industrial level and there will be a sharp increase in the market of albumin due to the latest outbreak of coronavirus. In terms of albumin protein preference, various methods for albumin purification were applied; the above methods such as purification by Precipitation using ammonium sulfate salt, ion exchange chromatography, affinity chromatography, through GFC and heat shock method. These all methods have their own importance, effectiveness and cost.</p>
</sec>
<sec id="sec-4">
  <title>Conclusion</title>
<p>In this article, we developed a concise overview of albumin, its market value and purification techniques of albumin.</p>
</sec>
</body>
<back>
<fn-group content-type="conflict-of-interest">
  <title>Conflict of Interest</title>
  <fn fn-type="conflict">
<p>The authors declare that they have no conflicts of interest.</p>
  </fn>
</fn-group>
<fn-group content-type="ethics-statement">
  <title>Ethics Statement</title>
  <fn fn-type="ethics">
<p>This study did not require formal ethics approval.</p>
  </fn>
</fn-group>
<fn-group content-type="data-availability">
  <title>Data Availability</title>
  <fn fn-type="data-availability-statement">
<p>Data sharing is not applicable to this article.</p>
  </fn>
</fn-group>
<app-group>
  <app id="app-suppl">
    <title>Supplementary Materials</title>
<supplementary-material id="suppl-pdf" content-type="pdf" xlink:href="https://gdddrjournal.com/pdf/gdddr/vwxOcbOfUw.pdf">
  <label>PDF</label>
  <caption>
    <title>Full Text PDF</title>
  </caption>
</supplementary-material>
  </app>
</app-group>
<ref-list>
  <title>References</title>
<ref id="Suri">
  <label>1</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Suri, S. S. H., &amp;Fenniri, B</person-group>
    <year>2007</year>
    <article-title>Singh, Nanotechnology-based drug delivery systems, J.Occup</article-title>
    <source>Med. Toxicol</source>
    Suri, S. S. H., &amp;Fenniri, B. (2007) Singh, Nanotechnology-based drug delivery systems, J.Occup. Med. Toxicol. 1, 2â€“16.
  </mixed-citation>
</ref>
<ref id="Roco">
  <label>2</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Roco, M. C</person-group>
    <year>2003</year>
    <article-title>. Nanotechnology: convergence with modern biology and medicine, Curr</article-title>
    <source>Opin. Biotechnol</source>
    Roco, M. C. (2003). Nanotechnology: convergence with modern biology and medicine, Curr. Opin. Biotechnol. 14, 337â€“346.
  </mixed-citation>
</ref>
<ref id="Torchilin">
  <label>3</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Torchilin, V. P</person-group>
    <year>2008</year>
    <article-title>. Nanotechnology in Drugs, second ed</article-title>
    <source>Imperial College Press,London</source>
    <page-range>ress</page-range>
    Torchilin, V. P. (2008). Nanotechnology in Drugs, second ed. Imperial College Press,London,
  </mixed-citation>
</ref>
<ref id="Sahoo">
  <label>4</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Sahoo, S. K. V</person-group>
    <year>2008</year>
    <article-title>. Labhasetwar, Nanotech approaches to drug delivery and imaging, Drug Discov</article-title>
    <source>Today</source>
    Sahoo, S. K. V. (2008). Labhasetwar, Nanotech approaches to drug delivery and imaging, Drug Discov. Today 8, 1112â€“1120
  </mixed-citation>
</ref>
<ref id="Couvreur">
  <label>5</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Couvreur, P. C</person-group>
    <year>2006</year>
    <article-title>. Vauthier, Nanotechnology: intelligent design to treat complex disease, Pharm</article-title>
    <source>Res</source>
    <page-range>C</page-range>
    Couvreur, P. C. (2006). Vauthier, Nanotechnology: intelligent design to treat complex disease, Pharm. Res. 23, 1417â€“1450.
  </mixed-citation>
</ref>
<ref id="Kumar">
  <label>6</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Kumar, R. M. N</person-group>
    <year>2000</year>
    <article-title>. Nano and microparticles as controlled drug delivery devices, J.Pharm</article-title>
    <source>Pharm. Sci</source>
    <page-range>harm</page-range>
    Kumar, R. M. N. (2000). Nano and microparticles as controlled drug delivery devices, J.Pharm. Pharm. Sci. 3, 234â€“258
  </mixed-citation>
</ref>
<ref id="Liu">
  <label>7</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Liu, Z, Y. Jiao, Y. Wang, C. Zhou, Z. Zhang</person-group>
    <year>2008</year>
    <article-title>. Polysaccharides-based nanoparticles as drug delivery systems, Adv</article-title>
    <source>Drug Deliv. Rev</source>
    <page-range>olysaccharides-based</page-range>
    Liu, Z, Y. Jiao, Y. Wang, C. Zhou, Z. Zhang. (2008). Polysaccharides-based nanoparticles as drug delivery systems, Adv. Drug Deliv. Rev. 60, 1650â€“1662
  </mixed-citation>
</ref>
<ref id="FernandezUrrusuno">
  <label>8</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Fernandez-Urrusuno, P., Calvo, C., Remunan- Lopez, J., L. &amp; Vila-Jato, M. J</person-group>
    <year>1999</year>
    <article-title>. Alonso, Enhancement of nasal absorption of insulin using chitosan nanoparticles, Pharm</article-title>
    <source>Res</source>
    <page-range>harm</page-range>
    Fernandez-Urrusuno, P., Calvo, C., Remunan- Lopez, J., L. &amp; Vila-Jato, M. J. (1999). Alonso, Enhancement of nasal absorption of insulin using chitosan nanoparticles, Pharm. Res. 16, 1576â€“1581
  </mixed-citation>
</ref>
<ref id="Farrugia">
  <label>9</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Farrugia, M. J</person-group>
    <year>1999</year>
    <article-title>. Groves, the activity of unloaded gelatin nanoparticles on murine B16-F0 melanoma growth in vivo, Anticancer</article-title>
    <source>Res</source>
    Farrugia, M. J. (1999). Groves, the activity of unloaded gelatin nanoparticles on murine B16-F0 melanoma growth in vivo, Anticancer. Res. 19, 1027â€“1031
  </mixed-citation>
</ref>
<ref id="Fattal">
  <label>10</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Fattal, C. Vauthier, I. Aynie, Y. Nakada, G. Lambert, C. Malvy, P</person-group>
    <year>1998</year>
    <article-title>. Couvreur, Biodegradable polyalkylcyanoacrylate nanoparticles for the delivery of oligonucleotides, J</article-title>
    <source>Control. Release</source>
    <page-range>olyalkylcyanoacrylate</page-range>
    Fattal, C. Vauthier, I. Aynie, Y. Nakada, G. Lambert, C. Malvy, P. (1998). Couvreur, Biodegradable polyalkylcyanoacrylate nanoparticles for the delivery of oligonucleotides, J. Control. Release 53, 137â€“ 143.
  </mixed-citation>
</ref>
<ref id="Breunig">
  <label>11</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Breunig, S. Bauer, A</person-group>
    <year>2008</year>
    <article-title>. Goepferich, Polymers and nanoparticles: intelligent tools for intracellular targeting? Eur</article-title>
    <source>J. Pharm. Biopharm</source>
    <page-range>olymers</page-range>
    Breunig, S. Bauer, A. (2008). Goepferich, Polymers and nanoparticles: intelligent tools for intracellular targeting? Eur. J. Pharm. Biopharm. 68, 112â€“128.
  </mixed-citation>
</ref>
<ref id="Kuijpers">
  <label>12</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Kuijpers, P.B. van Wachem, M.J.A. van Luyn, L.A. Brouwer, G.H.M. Engbers, J. Krijgsveld</person-group>
    <year>2000</year>
    <source>In vitro and in vivo evaluation of gelatin chondroitin sulphate hydrogels for controlled release of antibacterial proteins, Biomaterials</source>
    <page-range>B</page-range>
    Kuijpers, P.B. van Wachem, M.J.A. van Luyn, L.A. Brouwer, G.H.M. Engbers, J. Krijgsveld, (2000). In vitro and in vivo evaluation of gelatin chondroitin sulphate hydrogels for controlled release of antibacterial proteins, Biomaterials 21, 1763â€“1772
  </mixed-citation>
</ref>
<ref id="Elzoghby">
  <label>14</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Elzoghby, W.S. Abo El-Fotoh, N. A</person-group>
    <year>2011</year>
    <article-title>. Elgindy, Casein-based formulations as promising controlled release drug delivery systems, J</article-title>
    <source>Control. Release</source>
    <page-range>romising</page-range>
    Elzoghby, W.S. Abo El-Fotoh, N. A. (2011). Elgindy, Casein-based formulations as promising controlled release drug delivery systems, J. Control. Release 153, 206â€“216.
  </mixed-citation>
</ref>
<ref id="Vandelli">
  <label>15</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Vandelli, F. Rivasi, P. Guerra, F. Forni, R</person-group>
    <year>2001</year>
    <article-title>. Arletti, Gelatin microspheres crosslinked with d, l-glyceraldehyde as a potential drug delivery system: preparation, characterization, in vitro and in vivo studies, Int</article-title>
    <source>J. Pharm</source>
    <page-range>Guerra</page-range>
    Vandelli, F. Rivasi, P. Guerra, F. Forni, R. (2001). Arletti, Gelatin microspheres crosslinked with d, l-glyceraldehyde as a potential drug delivery system: preparation, characterization, in vitro and in vivo studies, Int. J. Pharm. 215, 175â€“184.
  </mixed-citation>
</ref>
<ref id="Sahin">
  <label>16</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Sahin, H. Selek, G. Ponchel, M.T. Ercan, M.A. Sargon, A. Hincal, H.S</person-group>
    <year>2002</year>
    <article-title>. Kas, Preparation, characterization and in vivo distribution of terbutaline sulfate loaded albumin microspheres, J</article-title>
    <source>Control. Release</source>
    <page-range>onchel</page-range>
    Sahin, H. Selek, G. Ponchel, M.T. Ercan, M.A. Sargon, A. Hincal, H.S. (2002). Kas, Preparation, characterization and in vivo distribution of terbutaline sulfate loaded albumin microspheres, J. Control. Release 82, 345â€“358.
  </mixed-citation>
</ref>
<ref id="Langer">
  <label>17</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Langer, S. Balthasar, V. Vogel, N. Dinauer, H. von Briesen, D</person-group>
    <year>2003</year>
    <article-title>. Schubert Optimization of the preparation process for human serum albumin (HSA) nanoparticles, Int</article-title>
    <source>J. Pharm</source>
    <page-range>reparation</page-range>
    Langer, S. Balthasar, V. Vogel, N. Dinauer, H. von Briesen, D. (2003). Schubert Optimization of the preparation process for human serum albumin (HSA) nanoparticles, Int. J. Pharm. 257, 169â€“180.
  </mixed-citation>
</ref>
<ref id="Rubino">
  <label>18</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Rubino, R. Kowalsky, J</person-group>
    <year>1993</year>
    <article-title>. Swarbrick, Albumin microspheres as a drug delivery system: relation among turbidity ratio, degree of cross-linking and drug release, Pharm</article-title>
    <source>Res</source>
    <page-range>harm</page-range>
    Rubino, R. Kowalsky, J. (1993). Swarbrick, Albumin microspheres as a drug delivery system: relation among turbidity ratio, degree of cross-linking and drug release, Pharm. Res. 10, 1059â€“1065.
  </mixed-citation>
</ref>
<ref id="Kommareddy">
  <label>19</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Kommareddy, M</person-group>
    <year>2005</year>
    <article-title>. Amiji, Preparation and evaluation of thiol-modified gelatin nanoparticles for intracellular DNA delivery in response to glutathione, Bioconjug</article-title>
    <source>Chem</source>
    <page-range>reparation</page-range>
    Kommareddy, M. (2005). Amiji, Preparation and evaluation of thiol-modified gelatin nanoparticles for intracellular DNA delivery in response to glutathione, Bioconjug. Chem. 16, 1423â€“1432.
  </mixed-citation>
</ref>
<ref id="Azarmi">
  <label>20</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Azarmi, X. Tao, H. Chen, Z. Wang, W.H. Finlay, R</person-group>
    <year>2006</year>
    <article-title>. LÃ¶benberg, W.H</article-title>
    <source>Roa, Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles, Int. J. Pharm</source>
    <page-range>owder</page-range>
    Azarmi, X. Tao, H. Chen, Z. Wang, W.H. Finlay, R. (2006). LÃ¶benberg, W.H. Roa, Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles, Int. J. Pharm. 319, 155â€“161.
  </mixed-citation>
</ref>
<ref id="Kratz">
  <label>21</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Kratz, I. Fichtner, P. Schumarcher, T</person-group>
    <year>1997</year>
    <article-title>. Roth, H.H</article-title>
    <source>Feibig, C. Unger, Antitumoractivity of acid labile transferrin and albumin doxorubicin conjugates in vitro and in vivo human tumor xerograft models, Eur. J. Cancer</source>
    <page-range>Schumarcher</page-range>
    Kratz, I. Fichtner, P. Schumarcher, T. (1997). Roth, H.H. Feibig, C. Unger, Antitumoractivity of acid labile transferrin and albumin doxorubicin conjugates in vitro and in vivo human tumor xerograft models, Eur. J. Cancer 33, S175
  </mixed-citation>
</ref>
<ref id="Rahimnejad">
  <label>22</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Rahimnejad, M. Jahanshahi, G.D</person-group>
    <year>2006</year>
    <article-title>. Najafpour, Production of biological nanoparticles from bovine serum albumin for drug delivery, Afr</article-title>
    <source>J. Biotechnol.5, 1918â€“1923</source>
    <page-range>roduction</page-range>
    Rahimnejad, M. Jahanshahi, G.D. (2006). Najafpour, Production of biological nanoparticles from bovine serum albumin for drug delivery, Afr. J. Biotechnol.5, 1918â€“1923
  </mixed-citation>
</ref>
<ref id="Fasano">
  <label>23</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Fasano, M., Curry, S., &amp; Terreno, E</person-group>
    <year>2005</year>
    <article-title>. The extraordinary ligand binding properties human serum albumin</article-title>
    <source>IUBMB Life</source>
    <page-range>roperties</page-range>
    Fasano, M., Curry, S., &amp; Terreno, E. (2005). The extraordinary ligand binding properties human serum albumin. IUBMB Life 57, 787â€“ 79
  </mixed-citation>
</ref>
<ref id="Droge">
  <label>24</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Droge, W., Schulze-Osthoff, K., &amp; Mihm, S</person-group>
    <year>1994</year>
    <article-title>. Functions of glutathione and glutathione disulfide in immunology and immunopathology</article-title>
    <source>FASEB J</source>
    Droge, W., Schulze-Osthoff, K., &amp; Mihm, S, (1994). Functions of glutathione and glutathione disulfide in immunology and immunopathology. FASEB J, 8, 1131â€“1138
  </mixed-citation>
</ref>
<ref id="Stohl">
  <label>25</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Stohl, W</person-group>
    <year>1996</year>
    <article-title>. Elliot JE: In vitro inhibition by intravenous immunoglobulin of human cell- dependent B cell differentiation induced by staphylococcal superantigens</article-title>
    <source>Clin Immunol Immunopathol</source>
    Stohl, W. (1996). Elliot JE: In vitro inhibition by intravenous immunoglobulin of human cell- dependent B cell differentiation induced by staphylococcal superantigens. Clin Immunol Immunopathol, 79, 122â€“133
  </mixed-citation>
</ref>
<ref id="Ephrem">
  <label>27</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Ephrem, A., Chamat, S., &amp; Miquel, C</person-group>
    <year>2008</year>
    <article-title>. Expansion of CD4+ CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis</article-title>
    <source>Blood</source>
    Ephrem, A., Chamat, S., &amp; Miquel, C, (2008). Expansion of CD4+ CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood, 111, 715â€“722
  </mixed-citation>
</ref>
<ref id="KraghHansen">
  <label>28</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Kragh-Hansen, U</person-group>
    <year>2013</year>
    <article-title>. Molecular and practical aspects of the enzymatic properties of human serum albumin and of albumin-ligand complexes</article-title>
    <source>Biochim Biophys Acta</source>
    <volume>1830</volume>
    <issue>12</issue>
    <fpage>5535</fpage>
    <lpage>44</lpage>
    Kragh-Hansen, U. (2013). Molecular and practical aspects of the enzymatic properties of human serum albumin and of albumin-ligand complexes. Biochim Biophys Acta , 1830(12), 5535-44
  </mixed-citation>
</ref>
<ref id="Liumbruno">
  <label>30</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Liumbruno, G. M., Bennardello, F., Lattanzio, A., Piccoli, P., &amp; Rossettias, G</person-group>
    <year>2009</year>
    <article-title>. Recommendations for the use of albumin and immunoglobulins</article-title>
    <source>Blood Transfus</source>
    <volume>7</volume>
    <issue>3</issue>
    <fpage>216</fpage>
    Liumbruno, G. M., Bennardello, F., Lattanzio, A., Piccoli, P., &amp; Rossettias, G. (2009). Recommendations for the use of albumin and immunoglobulins. Blood Transfus, 7(3):216- 34
  </mixed-citation>
</ref>
<ref id="Dugaiczyk">
  <label>31</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Dugaiczyk, A., Law, S. W., &amp; Dennison, O. E</person-group>
    <year>1982</year>
    <article-title>. Nucleotide sequence and the encoded amino acids of human serum albumin mrna</article-title>
    <source>Proc Natl Acad Sci USA</source>
    <volume>79</volume>
    <issue>1</issue>
    <fpage>71</fpage>
    <lpage>5</lpage>
    Dugaiczyk, A., Law, S. W., &amp; Dennison, O. E. (1982). Nucleotide sequence and the encoded amino acids of human serum albumin mrna. Proc Natl Acad Sci USA , 79(1):71-5.
  </mixed-citation>
</ref>
<ref id="Clowes">
  <label>32</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Clowes, G. H. J., Vucinic, M., &amp; Weidner, M. G</person-group>
    <year>1966</year>
    <article-title>. Circulatory and metabolic alterations associated with survival or death in peritonitis: Clinical analysis of 25 cases</article-title>
    <source>Ann Surg</source>
    <volume>163</volume>
    <issue>6</issue>
    <fpage>866</fpage>
    <lpage>85</lpage>
    Clowes, G. H. J., Vucinic, M., &amp; Weidner, M. G. (1966). Circulatory and metabolic alterations associated with survival or death in peritonitis: Clinical analysis of 25 cases. Ann Surg, 163(6):866-85
  </mixed-citation>
</ref>
<ref id="Chen">
  <label>33</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Chen, Z., He, Y., Shi, B., &amp; Yang, D</person-group>
    <year>2013</year>
    <article-title>. Human serum albumin from recombinant DNA technology:Challenges and strategies</article-title>
    <source>Biochim Biophys Acta</source>
    <volume>1830</volume>
    <issue>12</issue>
    <fpage>5515</fpage>
    <lpage>25</lpage>
    Chen, Z., He, Y., Shi, B., &amp; Yang, D. (2013). Human serum albumin from recombinant DNA technology:Challenges and strategies. Biochim Biophys Acta, 1830(12):5515-25
  </mixed-citation>
</ref>
<ref id="Raoufinia">
  <label>34</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Raoufinia, R., Mota, A., Nozari, S., Aghebati, M. L., Balkani, S., &amp; Abdolalizadeh, J</person-group>
    <year>2016</year>
    <article-title>. A methodological approach for purification and characterization of human serum albumin</article-title>
    <source>J Immunoassay Immunochem</source>
    <volume>37</volume>
    <issue>6</issue>
    <fpage>623</fpage>
    <lpage>35</lpage>
    Raoufinia, R., Mota, A., Nozari, S., Aghebati, M. L., Balkani, S., &amp; Abdolalizadeh, J. (2016). A methodological approach for purification and characterization of human serum albumin. J Immunoassay Immunochem, 37(6):623-35
  </mixed-citation>
</ref>
<ref id="He">
  <label>36</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">He, Y., Ning, T., Xie, T., Qiu, Q., Zhang, L., &amp; Sun, Y</person-group>
    <year>2011</year>
    <article-title>. Large-scale production offunctional human serum albumin from transgenic rice seeds</article-title>
    <source>Proc Nat Acad Sci USA</source>
    <volume>108</volume>
    <issue>47</issue>
    <fpage>19078</fpage>
    He, Y., Ning, T., Xie, T., Qiu, Q., Zhang, L., &amp; Sun, Y. (2011). Large-scale production offunctional human serum albumin from transgenic rice seeds. Proc Nat Acad Sci USA, 108(47):19078- 83
  </mixed-citation>
</ref>
<ref id="Hage">
  <label>38</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Hage, D. S., Anguizola, J. A., Bi, C., Li, R., Matsuda, R., &amp; Papastavros, E</person-group>
    <year>2012</year>
    <article-title>. Pharmaceutical and biomedical applications of affinitychromatography: Recent trends and developments</article-title>
    <source>J Pharm Biomed Anal</source>
    <page-range>apastavros</page-range>
    Hage, D. S., Anguizola, J. A., Bi, C., Li, R., Matsuda, R., &amp; Papastavros, E, (2012). Pharmaceutical and biomedical applications of affinitychromatography: Recent trends and developments. J Pharm Biomed Anal, 69, 93- 105
  </mixed-citation>
</ref>
<ref id="Abdolalizadeh">
  <label>39</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Abdolalizadeh, J., Nouri, M., Zolbanin, J. M., Barzegari, A., Baradaran, B., &amp; Barar, J</person-group>
    <year>2013</year>
    <article-title>. Targeting cytokines: Production and characterization of antiTNF-alpha scFvs by phage display technology</article-title>
    <source>Curr Pharm Des</source>
    <volume>19</volume>
    <issue>15</issue>
    <fpage>2839</fpage>
    <lpage>47</lpage>
    Abdolalizadeh, J., Nouri, M., Zolbanin, J. M., Barzegari, A., Baradaran, B., &amp; Barar, J. (2013). Targeting cytokines: Production and characterization of antiTNF-alpha scFvs by phage display technology. Curr Pharm Des, 19(15), 2839-47
  </mixed-citation>
</ref>
<ref id="Cuatrecasas">
  <label>42</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Cuatrecasas, P., Wilchek, M., &amp; Anfinsen, C. B</person-group>
    <year>1968</year>
    <article-title>. Selective enzyme purification byaffinity chromatography</article-title>
    <source>Proc Natl Acad Sci USA</source>
    <volume>61</volume>
    <issue>2</issue>
    <fpage>636</fpage>
    <lpage>43</lpage>
    Cuatrecasas, P., Wilchek, M., &amp; Anfinsen, C. B. (1968). Selective enzyme purification byaffinity chromatography. Proc Natl Acad Sci USA, 61(2), 636-43.
  </mixed-citation>
</ref>
<ref id="Moore">
  <label>43</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Moore, S., &amp; Stein, W. H</person-group>
    <year>1956</year>
    <article-title>. Column chromatography of peptides and proteins</article-title>
    <source>Adv. Protein Chem</source>
    <volume>11</volume>
    <fpage>191</fpage>
    <lpage>236</lpage>
    Moore, S., &amp; Stein, W. H. (1956). Column chromatography of peptides and proteins. Adv. Protein Chem., 11, 191-236.
  </mixed-citation>
</ref>
<ref id="William">
  <label>44</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">William, W</person-group>
    <year>2009</year>
    <source>Ward and Gavin Swiatek, Protein Purification, Current Analytical Chemistry</source>
    <volume>5</volume>
    <fpage>000</fpage>
    William, W. (2009). Ward and Gavin Swiatek, Protein Purification, Current Analytical Chemistry, 5,000-000
  </mixed-citation>
</ref>
<ref id="Kovacs">
  <label>45</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Kovacs, A., &amp; Guttman, A</person-group>
    <year>2013</year>
    <article-title>. Medicinal chemistry meets proteomics: Fractionation of the human plasma proteome</article-title>
    <source>Curr Med Chem</source>
    <volume>20</volume>
    <issue>4</issue>
    <fpage>483</fpage>
    <lpage>90</lpage>
    Kovacs, A., &amp; Guttman, A. (2013). Medicinal chemistry meets proteomics: Fractionation of the human plasma proteome. Curr Med Chem, 20(4), 483-90.
  </mixed-citation>
</ref>
<ref id="vasileva">
  <label>46</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">vasileva, R., Jakab, M., &amp; Hasko, F</person-group>
    <year>1981</year>
    <article-title>. Application of ionexchange chromatography for the production of human albumin</article-title>
    <source>J Chromatogr</source>
    <volume>216</volume>
    <fpage>279</fpage>
    <lpage>84</lpage>
    vasileva, R., Jakab, M., &amp; Hasko, F. (1981). Application of ionexchange chromatography for the production of human albumin. J Chromatogr, 216, 279-84.
  </mixed-citation>
</ref>
<ref id="Aghebati">
  <label>48</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Aghebati, M. A</person-group>
    <year>2013</year>
    <article-title>. Large scale generation and characterization of anti-human cd34 monoclonal antibody in ascetic fluid of balb/c mice</article-title>
    <source>Adv Pharm Bull</source>
    <volume>3</volume>
    <issue>1</issue>
    <fpage>211</fpage>
    <lpage>6</lpage>
    Aghebati, M. A. (2013). Large scale generation and characterization of anti-human cd34 monoclonal antibody in ascetic fluid of balb/c mice. Adv Pharm Bull, 3(1), 211-6.
  </mixed-citation>
</ref>
<ref id="Frerick">
  <label>49</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Frerick, C., Kreis, P., Gorak, A., &amp; Melzner, D</person-group>
    <year>2006</year>
    <article-title>. Simulation and optimisation of the downstream process for purification of human serum albumin by using ion exchange membrane adsorbers</article-title>
    <source>Desalination</source>
    <page-range>rocess</page-range>
    Frerick, C., Kreis, P., Gorak, A., &amp; Melzner, D. (2006). Simulation and optimisation of the downstream process for purification of human serum albumin by using ion exchange membrane adsorbers. Desalination, 200 (1-3), 468-9
  </mixed-citation>
</ref>
<ref id="Ramin">
  <label>51</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Ramin, R., Ali, M., Neda, K., Fatemeh, S., Sara, S., &amp; Jalal, A</person-group>
    <year>2016</year>
    <article-title>. Overview of protein ad its purification</article-title>
    <source>Adv pharm bull</source>
    <volume>6</volume>
    <issue>4</issue>
    <fpage>495</fpage>
    <lpage>507</lpage>
    Ramin, R., Ali, M., Neda, K., Fatemeh, S., Sara, S., &amp; Jalal, A. (2016). Overview of protein ad its purification. Adv pharm bull, 6(4), 495-507.
  </mixed-citation>
</ref>
<ref id="Denizli">
  <label>52</label>
  <mixed-citation publication-type="journal">
    <person-group person-group-type="author">Denizli, A</person-group>
    <year>2011</year>
    <article-title>. Plasma fractionation: Conventional and chromatographic methods for albumin purification</article-title>
    <source>Hacettepe J Biol Chem</source>
    <volume>39</volume>
    <issue>4</issue>
    <fpage>315</fpage>
    <lpage>41</lpage>
    Denizli, A. (2011). Plasma fractionation: Conventional and chromatographic methods for albumin purification. Hacettepe J Biol Chem 39(4), 315-41.
  </mixed-citation>
</ref>
</ref-list>
</back>
</article>